Cargando…

Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma

Immune checkpoint inhibitor (ICI) therapy may benefit patients with advanced esophageal squamous cell carcinoma (ESCC); however, novel biomarkers are needed to help predict the response of patients to treatment. Differentially expressed immune-related genes within The Cancer Genome Atlas ESCC datase...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Qinghua, Cai, Yingying, Shrestha, Sachin Mulmi, Shen, Duo, Zhao, Wei, Shi, Ruihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553461/
https://www.ncbi.nlm.nih.gov/pubmed/34722771
http://dx.doi.org/10.1155/2021/7430315
_version_ 1784591588188487680
author Ji, Qinghua
Cai, Yingying
Shrestha, Sachin Mulmi
Shen, Duo
Zhao, Wei
Shi, Ruihua
author_facet Ji, Qinghua
Cai, Yingying
Shrestha, Sachin Mulmi
Shen, Duo
Zhao, Wei
Shi, Ruihua
author_sort Ji, Qinghua
collection PubMed
description Immune checkpoint inhibitor (ICI) therapy may benefit patients with advanced esophageal squamous cell carcinoma (ESCC); however, novel biomarkers are needed to help predict the response of patients to treatment. Differentially expressed immune-related genes within The Cancer Genome Atlas ESCC dataset were selected using the weighted gene coexpression network and lasso Cox regression analyses. Based on these data, an immune-related gene prognostic index (IRGPI) was constructed. The molecular characteristics of the different IRGPI subgroups were assessed using mutation information and gene set enrichment analysis. Differences in immune cell infiltration and the response to ICI therapy and other drugs were also analyzed. Additionally, tumor and adjacent control tissues were collected from six patients with ESCC and the expression of these genes was verified using real-time quantitative polymerase chain reaction. IRGPI was designed based on CLDN1, HCAR3, FNBP1L, and BRCA2, the expression of which was confirmed in ESCC samples. The prognosis of patients in the high-IRGPI group was poor, as verified using publicly available expression data. KMT2D mutations were more common in the high-IRGPI group. Enrichment analysis revealed an active immune response, and immune infiltration assessment showed that the high-IRGPI group had an increased infiltration degree of CD8 T cells, which contributed to the improved response to ICI treatment. Collectively, these data demonstrate that IRGPI is a robust biomarker for predicting the prognosis and response to therapy of patients with ESCC.
format Online
Article
Text
id pubmed-8553461
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85534612021-10-29 Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma Ji, Qinghua Cai, Yingying Shrestha, Sachin Mulmi Shen, Duo Zhao, Wei Shi, Ruihua Biomed Res Int Research Article Immune checkpoint inhibitor (ICI) therapy may benefit patients with advanced esophageal squamous cell carcinoma (ESCC); however, novel biomarkers are needed to help predict the response of patients to treatment. Differentially expressed immune-related genes within The Cancer Genome Atlas ESCC dataset were selected using the weighted gene coexpression network and lasso Cox regression analyses. Based on these data, an immune-related gene prognostic index (IRGPI) was constructed. The molecular characteristics of the different IRGPI subgroups were assessed using mutation information and gene set enrichment analysis. Differences in immune cell infiltration and the response to ICI therapy and other drugs were also analyzed. Additionally, tumor and adjacent control tissues were collected from six patients with ESCC and the expression of these genes was verified using real-time quantitative polymerase chain reaction. IRGPI was designed based on CLDN1, HCAR3, FNBP1L, and BRCA2, the expression of which was confirmed in ESCC samples. The prognosis of patients in the high-IRGPI group was poor, as verified using publicly available expression data. KMT2D mutations were more common in the high-IRGPI group. Enrichment analysis revealed an active immune response, and immune infiltration assessment showed that the high-IRGPI group had an increased infiltration degree of CD8 T cells, which contributed to the improved response to ICI treatment. Collectively, these data demonstrate that IRGPI is a robust biomarker for predicting the prognosis and response to therapy of patients with ESCC. Hindawi 2021-10-21 /pmc/articles/PMC8553461/ /pubmed/34722771 http://dx.doi.org/10.1155/2021/7430315 Text en Copyright © 2021 Qinghua Ji et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ji, Qinghua
Cai, Yingying
Shrestha, Sachin Mulmi
Shen, Duo
Zhao, Wei
Shi, Ruihua
Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma
title Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma
title_full Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma
title_fullStr Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma
title_full_unstemmed Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma
title_short Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma
title_sort construction and validation of an immune-related gene prognostic index for esophageal squamous cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553461/
https://www.ncbi.nlm.nih.gov/pubmed/34722771
http://dx.doi.org/10.1155/2021/7430315
work_keys_str_mv AT jiqinghua constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma
AT caiyingying constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma
AT shresthasachinmulmi constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma
AT shenduo constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma
AT zhaowei constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma
AT shiruihua constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma